Edition:
United Kingdom

Genscript Biotech Corp (1548.HK)

1548.HK on Hong Kong Stock

13.94HKD
20 Aug 2018
Change (% chg)

HK$1.16 (+9.08%)
Prev Close
HK$12.78
Open
HK$12.90
Day's High
HK$14.14
Day's Low
HK$12.48
Volume
18,930,400
Avg. Vol
13,482,028
52-wk High
HK$34.00
52-wk Low
HK$4.25

Latest Key Developments (Source: Significant Developments)

Genscript Biotech Corp Proposes To Commence Share Repurchase Programme
Monday, 6 Aug 2018 

Aug 6 (Reuters) - Genscript Biotech Corp <1548.HK>::PROPOSES TO COMMENCE SHARE REPURCHASE PROGRAMME OF CO'S SHARES OF US$0.001 EACH FOR MAXIMUM CONSIDERATION OF HK$700 MILLION.  Full Article

Genscript Biotech Corp Announces Investment To Establish Biologics Manufacturing Center
Wednesday, 4 Jul 2018 

July 5 (Reuters) - Genscript Biotech Corp <1548.HK>::PROPOSES TO INVEST US$75 MILLION TO ESTABLISH A BIOLOGICS CLINICAL AND COMMERCIAL MANUFACTURING CENTER IN CHINA.TOTAL PRODUCTION CAPACITY OF MANUFACTURING CENTER IS ESTIMATED TO REACH 5,700 LITERS.  Full Article

Genscript Biotech Says Unit Enters Cooperation Agreement
Wednesday, 27 Jun 2018 

June 28 (Reuters) - Genscript Biotech Corp <1548.HK>::UNIT ENTERS COOPERATION AGREEMENT WITH AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY FOR CLINICAL TRIAL & RESEARCH.  Full Article

Genscript Biotech Announces Unit ‍Received Permission Of Clinical Trial Granted By China FDA
Tuesday, 13 Mar 2018 

March 13 (Reuters) - Genscript Biotech Corp <1548.HK>::UNIT ‍RECEIVED PERMISSION OF CLINICAL TRIAL GRANTED BY CHINA FDA WITH RESPECT TO LCAR- B38M CAR-T FOR AUTOLOGOUS INFUSION​.  Full Article

Genscript Biotech Announces Acquisition Of Customarray
Tuesday, 26 Dec 2017 

Dec 27 (Reuters) - Genscript Biotech Corp <1548.HK>::ANNOUNCES ACQUISITION OF 100% OF ENTIRE ISSUED SHARES OF CUSTOMARRAY, INC..  Full Article

Genscript Biotech Says US, Ireland Units ‍& Janssen Biotech Enter Collaboration & License Agreement ​
Thursday, 21 Dec 2017 

Dec 22 (Reuters) - Genscript Biotech Corp <1548.HK>::US, IRELAND UNITS ‍& JANSSEN BIOTECH ENTER COLLABORATION & LICENSE AGREEMENT TO DEVELOP MULTIPLE MYELOMA PRODUCTS ​.‍ACCORDING TO DEAL , JANSSEN SHALL UPFRONT PAYMENTS OF US$350 MILLION TO UNIT FOR RIGHTS GRANTED​.  Full Article

Janssen Enters Collaboration And License Agreement With China's Legend Biotech To Develop CAR-T Cancer Therapy
Thursday, 21 Dec 2017 

Dec 21 (Reuters) - Johnson & Johnson ::JANSSEN ENTERS WORLDWIDE COLLABORATION AND LICENSE AGREEMENT WITH CHINESE COMPANY LEGEND BIOTECH TO DEVELOP INVESTIGATIONAL CAR-T ANTI-CANCER THERAPY.JANSSEN BIOTECH - J&J REAFFIRMS FY 2017 ADJUSTED EARNINGS PER SHARE GUIDANCE OF $7.25 - $7.30.FY2017 EARNINGS PER SHARE VIEW $7.28 -- THOMSON REUTERS I/B/E/S.JANSSEN - ENTERED INTO WORLDWIDE COLLABORATION, LICENSE DEAL WITH UNITS OF GENSCRIPT BIOTECH CORPORATION.JANSSEN SAYS UNDER AGREEMENT, IT WILL MAKE AN UPFRONT PAYMENT OF $350 MILLION THAT WILL BE RECORDED IN Q4.JANSSEN SAYS COS ENTERED INTO A 50/50% COST-SHARING/PROFIT-SPLIT ARRANGEMENT, EXCEPT IN GREATER CHINA.JANSSEN SAYS IN GREATER CHINA, JANSSEN AND LEGEND HAVE A 30/70 PERCENT COST-SHARING/PROFIT-SPLIT ARRANGEMENT.  Full Article

Genscript Biotech Unit's‍ Application For Investigational New Drug Accepted By China FDA
Monday, 11 Dec 2017 

Dec 11 (Reuters) - Genscript Biotech Corp <1548.HK>::‍APPLICATION FOR INVESTIGATIONAL NEW DRUG BY UNIT ACCEPTED BY CHINA FDA.  Full Article

Genscript Biotech Corp updates on shareholding changes in GS Corp ​
Monday, 4 Dec 2017 

Dec 4 (Reuters) - Genscript Biotech Corp <1548.HK>::‍INFORMED THAT ADDITIONAL 50 MILLION SHARES & 25 MILLION SHARES OF GS CORP WERE TRANSFERRED TO ZHANG TRUST & WANG TRUST, RESPECTIVELY​.  Full Article

Genscript Biotech Corp says ‍Kanglitai informed by CFDA of approval on clinical trial
Wednesday, 25 Oct 2017 

Oct 25 (Reuters) - Genscript Biotech Corp <1548.HK>:Kanglitai informed by CFDA of approval on clinical trial; approved to commence clinical studies of KLT-1101​.  Full Article

Hong Kong market could open cash flood gates for U.S. biotechs

June 14 When U.S. biotech startup Sorrento Therapeutics named ex-Lehman Brothers executive Jiong Shao as its new finance chief about two months ago, it was widely seen as a move driven by his background in raising capital for Alibaba and Tencent.